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Abstract 
Ankaferd Blood Stopper (ABS), a hemostatic agent of plant origin, has been registered for the prevention of clinical 
hemorrhages. Currently there is no data regarding the ultrastructural analysis of ABS at the tissue level. The aim of this 
study is to assess renal tissue effects via scanning electron microscopy (SEM) analyses for the ABS and ABS nanohe-
mostat (formed by the combination of self-assembling peptide amphiphile molecules and ABS). SEM experiments 
were performed with FEI Nova NanoSEM 230, using the ETD detector at low vacuum mode with 30 keV beam energy. 
SEM analyses revealed that significant erythroid aggregation are present inside the capillary bed of the renal tissue. 
However, neither the signs of necrosis nor any other sign of tissue damage are evident in the surrounding renal tissue 
supplied by the microcapillary vasculature. Our study is important for several reasons. Firstly, in our study we used 
ABS nanohemostat which was recently developed. This study adds valuable information to the literature regarding 
ABS nanohemostat. Secondly, this study is the first ultrastructural analysis of ABS that was performed at the tissue 
level. Thirdly, we disclosed that ABS nanohemostat could induce vital erythroid aggregation at the renal tissue level 
as detected by SEM. Lastly, we detected that ABS nanohemostat causes no harm to the tissues including necrosis and 
any other detrimental effects.
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Background
Ankaferd Blood Stopper (ABS), is a hemostatic agent of 
plant origin, that has been registered for the prevention 
of clinical hemorrhages when the other techniques are 
ineffective (Beyazit et al. 2010, 2011; Haznedaroglu et al. 
2012; Goker et al. 2007). The ABS effects occurred via the 
protein agglutination and polymerization could modify 
vital erythroid aggregation inside vascular endothelium 
(Haznedaroglu et  al. 2012). The clinical efficacy of ABS 
in numerous systems had been demonstrated in the 
literature. For instance; ABS is very effective in the con-
trolling of hemorrhages within the gingival tissue (Amer 
et al. 2014), lung tissue (Uzun et al. 2014), tooth extrac-
tion (Kazancıoğlu et  al. 2013; Tek et  al. 2014; Beyazit 
et al. 2011), perineal tissue (Eyi et al. 2013), oral mucosa 
tissue (Leblebisatan et  al. 2012), gastrointestinal tissue 
(Karaman et al. 2012), thyroid tissue (Guler et al. 2011), 
nasopharyngeal tissue (Iynen et  al. 2011; Yasar and 
Ozkul 2011), nasal tissue (Teker et  al. 2010), peritonsil-
lary tissue (Teker et al. 2009). Also, it has been reported 
that partial nephrectomy operation in human was per-
formed without any complication with ABS (Huri et  al. 
2010). ABS is shown to be effective and safely used in the 
emergent beating heart coronary artery bypass grafting 
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(Atalay et  al. 2015). Moreover, ABS could control the 
hemorrhages in the cases who were using antiagregant 
treatment and undergone emergency bypass operation 
(Akpinar et al. 2015). Besides those valuable data for the 
efficacy of ABS, there is no available data regarding the 
ultrastructural analysis of ABS at tissue level.
ABS nanohemostat is a chimeric hemostatic agent. The 
medicine was developed by combining a self-assembling 
peptide amphiphile (PA) molecule with the traditional 
ABS (Huri et  al. 2013). ABS nanohemostat is useful in 
particular cases such as partial nephrectomy because tra-
ditional ABS could not be so effective due to insufficient 
contact surface between the ABS hemostatic liquid agent 
and the bleeding area (Huri et  al. 2013). Therefore the 
main function of PA is to carry active ABS agent onto the 
tissues in order to facilitate hemostatic action in a given 
tissue.
The aim of this study is to assess renal tissue effects 
via Scanning Electron Microscopy (SEM) analyses for 
the ABS nanohemostat formed by the combination of 
self-assembling peptide amphiphile (PA) molecules and 
ABS. Elucidation of the safety of ABS nanohemostat is 
extremely important at the tissue level since Ankaferd 
has already been utilized in a vast variety of human clini-
cal trials such as heart surgery, tonsillectomy, thyroidec-
tomy, episiotomy and many others.
Methods
Animals and materials
The specimens were acquired from previously performed 
study by our group (Huri et al. 2013). All animal experi-
mentations described in this paper were carried out in 
accordance with national guidelines for the use and care 
of laboratory animals and were approved by the local ani-
mal review and “Ankara Hospital Animal Study Ethics 
Committee, Ankara/Turkey”. All procedures were in full 
compliance with Turkish Law 6343/2, Veterinary Medi-
cine Deontology Regulation 6.7.26, and with the Helsinki 
Declaration of World Medical Association recommenda-
tions on animal studies. The animals were obtained from 
the center of medical experimental research of Ankara 
Training and Research Hospital. The rats were housed 
in stainless steel cages in an animal room maintained at 
a temperature of 22–24 °C with 12-h light/dark periods. 
All were fed with the same amount of laboratory pellet 
diet and with water supplied ad libitum for a minimum of 
5 days before partial nephrectomy (PN). In the previously 
published study by our group, 9-Fluorenylmethoxycar-
bonyl (Fmoc), ter. Butoxycarbonyl (Boc) protected amino 
acids, Rink Amide MBHA resin and 2-(1H-Benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU) were purchased from NovaBiochem or ABCR. 
The other chemicals were purchased from Fisher, Merck, 
Alfa Aesar or Aldrich and used as provided. A total of 
24 Wistar rats weighing 200–300  g were divided into 4 
groups of 6 each and underwent PN. One surgeon with 
an assistant performed all the surgical procedures. All 
operations were performed under general anaesthe-
sia with injection of 50  mg/kg intramuscular ketamine 
hydrochloride. After sterile preparation and draping, a 
midline incision was made on the abdomen. For each rat, 
renal artery and vein were exposed by hilar vascular dis-
section. Subsequently renal artery and vein were clamped 
with Rommel vascular clamp. The lower third of the left 
kidney was resected in guillotine fashion with a single 
stroke of an amputating knife. Four different hemostatic 
techniques were applied to the chronological groups.
Group 1 (G1): Left PN with hilar vascular control 
including intracorporeal suturing of the renal paren-
chyma and collecting duct.
Group 2 (G2): Conventional PN with only 0.5 ml tra-
ditional Ankaferd hemostat (ABS) application without 
suturing.
Group 3 (G3): Conventional PN with ABS 
(0.25 ml) + peptide (0.25 ml) gel (ABS Nanohemostat) 
mixture application with no suturing.
Group 4 (G4): Conventional PN with only 0.5 ml pep-
tide solution application.
Two objective parameters were recorded during the 
surgical procedure: warm ischemia time (WIT) and 
amount of bleeding (AOB). The unit of WIT was the 
“second” while the AOB was measured with the bleeding 
area (cm2) onto the sponges. After the procedures, the 
sponges were used to collect all visible clots and blood 
to be measured for the bleeding surface detection. The 
abdominal incision was afterwards closed with surgical 
sutures. All the rats were allowed to feed and drink water 
for the following 4  weeks. After then, each rat was sac-
rificed and total nephrectomy was performed for histo-
pathological examination.
The hemostatic methods during PN
Each hemostatic method was used during the period 
of warm ischemia (WI). WI started with clamping the 
renal artery and vein, and finished with taking the clamp 
out. In G1, traditional hemostasis method was used as 
compression onto the renal excised area and suturing 
the renal vessels and collecting duct with absorbable 
sutures. In G2, 2  ml of ABS was dropped to the ampu-
tated renal margin steadily until bleeding stopped. In 
G3, ABS (2 ml) + Nanopeptide gel mixture (ABS nano-
hemostat) was applied onto the injured area. And in 
G4, only nanopeptide gel was used to control bleeding. 
Other hemostatic methods including sponges, Surgicel, 
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electrocautery and any other sources were not used to 
control bleeding in the present study.
Scanning electron microscopy (SEM) imaging of rat kidney 
tissues
The portions of the kidneys from the rats in the studied 
groups were cut into small blocks, immersed and rinsed 
to be examined in the SEM analyses. The SEM experi-
ments were performed with FEI Nova NanoSEM 230, 
using the ETD detector at low vacuum mode with 30 keV 
beam energy.
Results
Warm ischemia time for each group was 232.8  ±  56.3, 
65.6 ± 11.4, 75.5 ± 17.2, 58.1 ± 17.6 s in Group 1,2,3 and 
4, respectively (p:0.003). The amount of bleeding for each 
group was 7.3 ± 3.3, 5.7 ± 2.3, 5.2 ± 3.2, 16.4 ± 7.7 cm2 
in Group 1, 2, 3 and 4, respectively (p: 0.035).
The SEM analyses of the G2 (Conventional PN with 
only 0.5  ml traditional Ankaferd hemostat (ABS) appli-
cation without suturing) and G3 (Conventional PN with 
ABS (0.25 ml) + peptide (0.25 ml) gel (ABS Nanohemo-
stat) mixture application with no suturing) revealed that 
significant erythroid aggregation are present inside the 
capillary bed of the renal tissue upon the application of 
both ABS and ABS nanohemostat. However, neither the 
signs of necrosis nor any other sign of tissue damage are 
evident in the surrounding renal tissue supplied by the 
microcapillary vasculature in both ABS and ABS nano-
hemostat. Furthermore, the appearance of the nucleus, 
cytoplasm of the vascular endothelial cells and their orga-
nelles are completely normal with both agents (Fig. 1).
In the SEM analyses of the both research groups of G2 
and G3, proximal tubule cells are observed which consti-
tutes a large part of the cortical parenchyma. The nucleus 
of cells, the cell membrane and intracellular organelles 
have normal view which is observed in each level (Fig. 2). 
There are a large number of normal-looking mitochon-
dria in the cytoplasm of cells which is lining the proxi-
mal tubules. Many vesicles are observed in the cytoplasm 
which is located in the apical portion of the cells. A large 
number of normal-looking microvilli creates brush bor-
der and is viewed on the apical cell membrane of the 
proximal tubule. Topical ABS application had no nega-
tive effects to the renal parenchyma at the level of renal 
cortex.
In the SEM analyses of the both research groups of 
G2 and G3, in the glomerular capillary endothelium, 
fenestrated endothelial cells, basement membrane and 
tripartite structure created by the podocytes viewed 
completely normal (Fig.  3). The mesangial cells are also 
localized in mesangium was normal. The damage was not 
present on the glomerules, mesangial cells and critique 
renal tissues like as endothelial structures. Neither ABS 
nor ABS nanohemostat caused any damage at the level of 
cell and intracellular organelles in the kidneys.
The SEM analyses of the G1 (Left PN with hilar vas-
cular control including intracorporeal suturing of the 
renal parenchyma and collecting duct) and G4 (Conven-
tional PN with only 0.5 ml peptide solution application) 
served as the control groups for the comparison of ABS 
and ABS nanohemostat-induced renal tissue effects. In 
the both control groups; although glomerulus are gen-
erally normal, fenestrates are spacious in some place of 
basal lamina on the side of the endothel and edema pre-
sent. Pedicels are seen normal (Fig. 4). Though proximal 
tubules are seen normal in most of the field, intracellular 
edema is seen in some places (Fig. 5).
Discussion
The efficacy of ABS was demonstrated in many studies. 
In a study which was conducted with 160 patients, it was 
shown that ABS is effective for gingival bleedings (Amer 
et al. 2014). In another study which was conducted by 25 
patients who were undergone bronchoscopy procedure, 
ABS has successfully controlled the bleeding episodes 
of the cases (Uzun et  al. 2014). There are three differ-
ent clinical studies which confirms ABS as a successful 
hemostatic agent that was conducted with 25, 50 and 
113 patients, respectively (Kazancıoğlu et  al. 2013; Tek 
et al. 2014; Beyazit et al. 2011). ABS could also be used in 
gynecological cases. For example, in a study that was con-
ducted on 40 cases with episiotomy, ABS again controlled 
the bleeding episodes (Eyi et  al. 2013). In the literature 
there are some studies that was conducted on younger 
population also. For example, oral hemorrhagic episodes 
of 12 children were controlled by ABS in a study (Lebleb-
isatan et al. 2012). Also, in a study with 47 children, the 
tonsillectomy procedures were successfully completed 
with ABS (Teker et al. 2009). Gastrointestinal and thyroi-
dal tissue is also the sites of use for ABS. Hemorrhagic 
episodes in 30 cases who were performed gastric endos-
copy and 61 cases who were undergone total thyroidec-
tomy, were taken under control with ABS (Karaman et al. 
2012; Guler et al. 2011). Otorhinolaryngology is another 
area that ABS is used. In two different studies which was 
conducted with 90 and 60 cases who were undergone 
adenoidectomy, the operations were performed without 
any complication with ABS (Iynen et al. 2011; Yasar and 
Ozkul 2011). The most astonishing reports regarding 
ABS are the emergent bypass procedures. There are two 
studies regarding this issue. In both studies 25 patients 
were included and ABS is shown to reduce bleedings sig-
nificantly (Atalay et al. 2015; Akpinar et al. 2015). Apart 
from these clinical efficiency data, unfortunately in the 
literature there are limited data regarding safety in tissue 
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level. Also ABS induced vital erythroid aggregation was 
never shown at ultrastructural level. In previously pub-
lished clinical studies, the confirmation of safety issue in 
tissue level is a compelling problem since there are ethi-
cal obstacles about acquiring samples of patient’s tissues 
in clinical conditions of emergency and hemorrhage.
ABS nanohemostat is chimeric molecule that was 
synthesized by combining a self-assembling peptide 
amphiphile (PA) molecule with the traditional Ankaferd 
hemostat. The efficacy of ABS nanohemostat was shown 
previously in an experimental partial nephrectomy model 
(Huri et  al. 2013). In our study, we have observed the 
erythroid aggregation in previously collected renal tissue. 
Moreover, we have observed no tissue damage by ABS 
nanohemostat including necrosis.
Although there is no ultrastructural analysis of the 
effect of ABS in the literature previously, the effect of 
ABS on blood vessels have already been elegantly demon-
strated under the light microscopy by Saçak et al. (2014). 
In their study, the hemostatic effect of ABS on the vas-
cular tissue were investigated. ABS effect of preventing 
the microvascular leakage on an anastomosis site and its 
long-term impact had been demonstrated. Although the 
mean bleeding time of the ABS group in that study was 
shorter, the pseudo-aneurysm formation on the vascu-
lar tissue was observed three weeks after the operation. 
Histological examination revealed the increased inflam-
matory cell infiltration, tunica media degeneration and 
contraction of the tunica intima in ABS group (Saçak 
et al. 2014).
We had four study groups in this research. SEM analy-
ses of G1 (Left PN with hilar vascular control including 
intracorporeal suturing of the renal parenchyma and 
collecting duct) and G4 (Conventional PN with only 
0.5  ml peptide solution application) disclosed compara-
ble intracellular edema. Both of the G1 and G4 groups 
were served as the controls in order to test the effects 
of ABS and ABS nanohemostat at the renal tissue level. 
The investigation groups namely; G3 [Conventional PN 
with ABS (0.25 ml) + peptide (0.25 ml) gel (ABS Nano-
hemostat) mixture application with no suturing] and 
G4 (Conventional PN with only 0.5 ml peptide solution 
application) were the main research focus in this study. 
SEM analyses of the G3 and G4 study groups revealed 
the significant finding that erythroid aggregation are 
present inside the capillary bed of the renal tissue with 
Fig. 1 Red blood cell aggregation are present inside the capillary bed of the renal tissue upon the application of Ankaferd hemostat. The appear-
ance of the nucleus, cytoplasm of the vascular endothelial cells and their organelles are completely normal (e erythrocyte)
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the topical application of both ABS and ABS nanohe-
mostat. The main hemostatic action of vital erythroid 
aggregation upon the exposure of ABS onto tissues has 
been elucidated via SEM analyses at the renal tissue level 
in this present study. Since the main supposed function 
of peptide amphiphile (PA) molecule is to carry active 
ABS onto the tissue compartments, its addition did not 
effected the hemostatic action of ABS and served just 
as a ‘drug carrier’. Erythroid aggregation is provided 
by erythroid receptors and proteins (spectrin, ankyrin, 
actin) which is fixed by functional proteomics of ABS 
(Demiralp et al. 2010). Erythrocyte aggregation tightens 
on fibrinogen gamma and resulting erythroid network 
is provided to interact with the vascular endothelium 
(Demiralp et  al. 2012). Because gamma fibrinogen has 
antithrombin I effect, a coagulation-axis thrombotic 
conditions and endothelial damage does not evolved 
in this process. At the level of cellular and intracellular 
organelles ABS damage does not develop. The repair of 
hurtful process secondary to trauma is carried out by 
physiological hemostasis. Edema following the use of 
topical hemostatic agents is thought to be associated with 
endothelial activation. Urotensin II which is inside ABS 
can be held responsible in this situation (Demiralp et al. 
2012). Tubular edema development following the use of 
topical hemostatic agents is thought to be related to the 
renal tubular apoptosis which is previously shown by 
Huri et al. (2009).
Our study is important for several reasons. Firstly, 
in our study we used ABS nanohemostat which was 
recently developed. There are very few data regarding 
ABS nanohemostat. Our study adds valuable informa-
tion to the literature regarding ABS nanohemostat. 
Secondly, this is the first study that reveals the ultras-
tructural analysis of ABS at tissue level. Previously, 
ultrastructural analysis of ABS was only performed in 
blood samples in the literature. There are no electron 
microscopy observations regarding ABS at tissue level. 
Thirdly, first time in the literature we detected ABS 
nanohemostat induced vital erythroid aggregation at 
tissue level by SEM. Lastly and the most important find-
ing of our study is that we detected ABS nanohemostat 
Fig. 2 The nucleus of cells, the cell membrane and intracellular organelles have normal view which is observed in each level at the Ankaferd hemo-
stat applied renal tissue. Proximal tubule cells are observed which constitutes a large part of the cortical parenchyma. There are a large number of 
normal-looking mitochondria in the cytoplasm of cells which is lining the proximal tubules. Many vesicles are observed in the cytoplasm which is 
located in the apical portion of the cells. A large number of normal-looking microvilli creates brush border and is viewed on the apical cell mem-
brane of the proximal tubule (m mitochondria, black arrows microvilli)
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causes no harm to tissues including necrosis and any 
other effects. This is the first ultrastructural analysis 
of ABS nanohemostat regarding the safety issue at tis-
sue level. By these findings in our study we confirm 
that ABS nanohemostat is a safe hemostatic agent and 
could be used especially in the renal tissue without any 
doubts. However there are still many efforts to spend 
in order to increase our knowledge about ABS nanohe-
mostat. Phase 1, 2 and 3 studies should be performed 
regarding ABS nanohemostat since this agent should be 
considered as a new agent apart from traditional ABS. 
Moreover, we have revealed the efficient and safety of 
Fig. 3 In the glomerular capillary endothelium, fenestrated endothelial cells, basement membrane and tripartite structure created by the podo-
cytes viewed as completely normal (e erythrocyte, black arrows podocytes)
Fig. 4 Glomerulus are generally normal, fenestrates are spacious in 
some place of basal lamina on the side of the endothel and edema 
present. Pedicels are seen normal (black arrows; fenestrates, * pedi-
cels)
Fig. 5 Though proximal tubules are seen normal in most of the field, 
intracellular edema is seen in some places (black arrows edema)
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ABS nanohemostat in renal tissue; however these effects 
should be confirmed in other tissues by other studies. 
Our findings may be the starting point for upcoming 
future studies which would add valuable information 
about ABS nanohemostat.
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